J. Fleishaker

发表

Models and methods for predicting drug transfer into human milk.

J. Fleishaker, J. C. Fleishaker, 2003, Advanced drug delivery reviews.

Electrocardiographic Identification of Drug‐Induced QT Prolongation: Assessment by Different Recording and Measurement Methods

Borje Darpo, Nenad Sarapa, Wojciech Zareba, 2004, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents

R. Poland, Keh‐ming Lin, J. Fleishaker, 2001, Psychopharmacology.

Clinical Pharmacokinetics of Reboxetine, a Selective Norepinephrine Reuptake Inhibitor for the Treatment of Patients with Depression

J. Fleishaker, Joseph C. Fleishaker, J. C. Fleishaker, 2000, Clinical pharmacokinetics.

Safety and Efficacy of PNU-142633, a Selective 5-HT1D Agonist, in Patients with Acute Migraine

J. Couch, B. Gomez-Mancilla, N. Cutler, 2001, Cephalalgia : an international journal of headache.

Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.

L. Wienkers, J. Fleishaker, G. Peters, 1996, The Journal of pharmacology and experimental therapeutics.

Lack of effect of reboxetine on cardiac repolarization

J. Fleishaker, N. Azie, S. Francom, 2001, Clinical pharmacology and therapeutics.

The Importance of Biomarkers in Translational Medicine

J. Fleishaker, J. C. Fleishaker, 2012 .

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine

J. Fleishaker, L. K. Hulst, J. C. Fleishaker, 2004, European Journal of Clinical Pharmacology.

Pharmacokinetics of Tirilazad and U‐89678 in Ischemic Stroke Patients Receiving a Loading Regimen and Maintenance Regimen of 10 mg/kg/day of Tirilazad

J. Fleishaker, G. Peters, 1996, Journal of clinical pharmacology.

Evaluation of a Potential Interaction Between Erythromycin and Glyburide in Diabetic Volunteers

J. Fleishaker, J. P. Phillips, Joseph C. Fleishaker, 1991, Journal of clinical pharmacology.

The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons

R. Poland, Keh‐ming Lin, J. Fleishaker, 1997, Psychopharmacology.

Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment

G. Houin, P. Rampal, J. Fleishaker, 2000 .

Evaluation of the Pharmacokinetics and Tolerability of Tirilazad Mesylate, a 21‐Aminosteroid Free Radical Scavenger: II. Multiple‐Dose Administration

R. Steenwyk, J. Fleishaker, G. Peters, 1993, Journal of clinical pharmacology.

Evaluation of the Pharmacokinetics and Tolerability of Tirilazad Mesylate, a 21‐Aminosteroid Free Radical Scavenger: I. Single‐Dose Administration

J. Fleishaker, G. Peters, K. Cathcart, 1993, Journal of clinical pharmacology.

Evaluation of the Potential Pharmacokinetic Interaction between Almotriptan and Fluoxetine in Healthy Volunteers

J. Fleishaker, N. Azie, K. Ryan, 2001, Journal of clinical pharmacology.

Hormonal Effects on Tirilazad Clearance in Women: Assessment of the Role of CYP3A

L. Wienkers, P. Pearson, J. Fleishaker, 1999, Journal of clinical pharmacology.

Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics.

I. Poggesi, J. Fleishaker, M. Mucci, 1999, Biopharmaceutics & drug disposition.

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Adinazolam in Elderly Subjects

J. Fleishaker, Randall B. Smith, J. P. Phillips, 1989, Pharmaceutical Research.

Factors affecting the milk-to-plasma drug concentration ratio in lactating women: physical interactions with protein and fat.

P. McNamara, J. Fleishaker, N. Desai, 1987, Journal of pharmaceutical sciences.

Pharmacokinetics of Single‐Dose Reboxetine in Volunteers with Renal Insufficiency

G. Houin, F. Fiorentini, I. Poggesi, 2000, Journal of clinical pharmacology.

Pharmacokinetics of reboxetine in healthy, elderly volunteers

G. Houin, J. Fleishaker, J. Bergmann, 2000, European Journal of Drug Metabolism and Pharmacokinetics.

Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans

J. Fleishaker, B. D. Herman, M. T. Brown, 1999, Clinical pharmacology and therapeutics.

Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens

B. Guglielmo, J. Fleishaker, J. Flaherty, 1988, Antimicrobial Agents and Chemotherapy.

Cardiovascular effect of almotriptan in treated hypertensive patients

J. Fleishaker, N. Azie, S. Francom, 2002, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Tirilazad: Effects of Weight, Gender, Concomitant Phenytoin, and Subarachnoid Hemorrhage

J. Fleishaker, J. Fiedler-Kelly, T. Grasela, 1999, Pharmaceutical Research.

Effect of Gender and Menopausal Status on the Pharmacokinetics of Tirilazad Mesylate in Healthy Subjects.

J. Fleishaker, G. Peters, Laura K. Hulst-Pearson, 1995, American journal of therapeutics.

The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

E. Wong, M. Hajós, J. Fleishaker, 2006, CNS drug reviews.

N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10–50 mg oral doses in healthy volunteers

J. Fleishaker, Thomas C. Smith, H. Friedman, 2005, Psychopharmacology.

Pharmacokinetic and Pharmacodynamic Comparison of Immediate-Release and Sustained-Release Adinazolam Mesylate Tablets After Single- and Multiple-Dose Administration

J. Fleishaker, C. Wright, 1992, Pharmaceutical Research.

Extent and Variability of the First-Pass Elimination of Adinazolam Mesylate in Healthy Male Volunteers

J. Fleishaker, H. Friedman, S. Pollock, 1991, Pharmaceutical Research.

Adinazolam pharmacokinetics and behavioral effects following administration of 20–60 mg oral doses of its mesylate salt in healthy volunteers

J. Fleishaker, J. P. Phillips, J. C. Fleishaker, 2004, Psychopharmacology.

Pharmacokinetics and Psychomotor Performance of Alprazolam: Concentration—Effect Relationship

E. Antal, J. Fleishaker, C. Wright, 1997, Journal of clinical pharmacology.

Evaluation of the development of acute tolerance to the psychomotor effects of midazolam following intravenous infusions in healthy volunteers

J. Fleishaker, G. Peters, J. H. Chambers, 1995 .

Separation of the Pharmacokinetic/Pharmacodynamic Properties of Oral and IV Adinazolam Mesylate and N-Desmethyladinazolam Mesylate in Healthy Volunteers

J. Fleishaker, T. C. Smith, H. Friedman, 1992 .

Interaction between Ketoconazole and Almotriptan in Healthy Volunteers

J. Fleishaker, N. Azie, B. D. Herman, 2003, Journal of clinical pharmacology.

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.

J. Fleishaker, N. Azie, D. Bell, 2001, British journal of clinical pharmacology.

Drug–Drug Interactions: Designing Development Programs and Appropriate Product Labeling

J. M. Hutzler, J. Fleishaker, J. Cook, 2011 .

Drug–Drug Interactions: Designing Development Programs and Appropriate Product Labeling

J. M. Hutzler, J. Fleishaker, J. Cook, 2011 .

Pharmacokinetics and Pharmacodynamics of Alprazolam Following Single and Multiple Oral Doses of a Sustained‐Release Formulation

M. Eller, J. Fleishaker, J. P. Phillips, 1989, Journal of clinical pharmacology.

In vivo evaluation in the lactating rabbit of a model for xenobiotic distribution into breast milk.

P. McNamara, J. Fleishaker, 1988, The Journal of pharmacology and experimental therapeutics.

Effect of altered serum protein binding on propranolol distribution into milk in the lactating rabbit.

P. McNamara, J. Fleishaker, 1988, The Journal of pharmacology and experimental therapeutics.

Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects

H. Weingartner, K. Sirocco, P. Garzone, 1995, Psychopharmacology.

Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine

E. Antal, R. Steenwyk, J. Fleishaker, 2005, Psychopharmacology.

Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in healthy volunteers

J. Fleishaker, T. C. Smith, H. Friedman, 2004, European Journal of Clinical Pharmacology.

Evaluation of the Potential Pharmacokinetic/Pharmacodynamic Interaction between Fluoxetine and Reboxetine in Healthy Volunteers

J. Fleishaker, M. Mucci, L. K. Pearson, 1999 .

Effect of age and gender on tirilazad pharmacokinetics in humans

P. Ward, D. M. Wright, J. Fleishaker, 1994, Clinical pharmacology and therapy.

Alprazolam absorption kinetics affects abuse liability *

R. Griffiths, S. Evans, J. Fleishaker, 1995, Clinical pharmacology and therapeutics.

The Pharmacokinetics of 2.5‐ to 10‐mg Oral Doses of Minoxidil in Healthy Volunteers

N. Andreadis, J. Fleishaker, I. Welshman, 1989, Journal of clinical pharmacology.

Disposition of Minoxidil in Patients with Various Degrees of Renal Function

G. Matzke, C. Halstenson, J. Opsahl, 1989, Journal of clinical pharmacology.

Psychomotor and Memory Effects of Two Adinazolam Formulations Assessed by a Computerized Neuropsychological Test Battery

N. Cutler, J. Fleishaker, J. Sramek, 1993, Journal of clinical pharmacology.

Performance Characteristics for Some Typical QT Study Designs Under the ICH E‐14 Guidance

M. Hutmacher, M. Agin, R. Lalonde, 2008, Journal of clinical pharmacology.

Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics

P. McNamara, J. Fleishaker, 1985, Antimicrobial Agents and Chemotherapy.

Comparing Methods of Measurement for Detecting Drug‐Induced Changes in the QT Interval: Implications for Thoroughly Conducted ECG Studies

B. Darpo, J. Fleishaker, N. Azie, 2004, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers.

J. Fleishaker, G. Peters, L. K. Hulst, 1994, International journal of clinical pharmacology and therapeutics.

Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N‐Desmethyladinazolam in Man

D. Greenblatt, R. Shader, K. Venkatakrishnan, 1998, The Journal of pharmacy and pharmacology.

Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2.

L. Wienkers, P. Pearson, R. Steenwyk, 1998, The Journal of pharmacology and experimental therapeutics.

In Vitro and in Vivo Evaluation of Whole and Half Tablets of Sustained-Release Adinazolam Mesylate

John W. Skoug, M. Borin, J. Fleishaker, 1991, Pharmaceutical Research.

Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT1B/1D Receptor Agonist for the Treatment of Migraine

J. Fleishaker, Janet D McEnroe, J. C. Fleishaker, 2005, Clinical pharmacokinetics.

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers

J. Fleishaker, N. Azie, B. J. Carel, 2000, Clinical pharmacology and therapeutics.

The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers

J. Fleishaker, G. Peters, L. K. Hulst, 1994, Clinical pharmacology and therapeutics.

Pharmacokinetics of reboxetine in elderly patients with depressive disorders.

I. Poggesi, J. Fleishaker, C. Pellizzoni, 2000, International journal of clinical pharmacology and therapeutics.

Studies with [11C]alprazolam: an agonist for the benzodiazepine receptor.

B. Kinsey, A. Valentine, J. Fleishaker, 1995, Nuclear medicine and biology.

Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers.

S. Stahl, R. Hauger, J. Fleishaker, 1993, Clinical neuropharmacology.

Comparison of Adinazolam Pharmacokinetics and Effects in Healthy and Cirrhotic Subjects

P. Kroboth, J. Fleishaker, Randall B. Smith, 1991, Journal of clinical pharmacology.

Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction.

J. Fleishaker, G. Peters, L. K. Pearson, 1995, Journal of pharmaceutical sciences.

Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults.

J. Fleishaker, R. N. Straw, C. J. Cross, 1997, Journal of pharmaceutical sciences.

Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis

J. Fleishaker, G. Peters, L. K. Pearson, 1996, European Journal of Clinical Pharmacology.

Gender does not affect the degree of induction of tirilazad clearance by phenobarbital

J. Fleishaker, G. Peters, L. K. Pearson, 1996, European Journal of Clinical Pharmacology.

Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.

L. Wienkers, J. Fleishaker, G. Peters, 1998, The Journal of pharmacology and experimental therapeutics.

Kinetics and Dynamics of Intravenous Adinazolam, N‐Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers

D. Greenblatt, B. Ehrenberg, J. Harmatz, 2005, Journal of clinical pharmacology.

Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice

S Madani, S. Cohen, J. Fleishaker, 2010, Clinical pharmacology and therapeutics.

Anticipatory Anxiety in Moderately to Highly-Anxious Oral Surgery Patients as a Screening Model for Anxiolytics: Evaluation of Alprazolam

P. Desjardins, J. Fleishaker, R. Mohanlal, 2003, Journal of clinical psychopharmacology.

Effects of Acute and Chronic Alprazolam Treatment on Cerebral Blood Flow, Memory, Sedation, and Plasma Catecholamines

M. Graham, A. Radant, M. Dubach, 1993, Neuropsychopharmacology.

Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F.

B. Gomez-Mancilla, J. Fleishaker, S. Freestone, 1999, International journal of clinical pharmacology and therapeutics.